"This takeover of Promera is great for both consumers and Vireo,” said Mark Faulkner, president of VSI. “Ever since CON-CRĒT became the #1 specialty creatine in the market, we have seen knock-off creatine-HCl from infringing overseas sources with both low purity and a variety of contaminants. Customers can trust the quality of the product that Promera is delivering as well as those major brands that have licensed patented C-HCl as an ingredient.”
Vireo synthesized creatine HCl in January 2003 and spent several years researching the unique properties of this molecule with scientists at University of Nebraska Medical Center in Omaha and Vanderbilt University in Nashville. As its attributes started showing promise, Vireo branded C-HCl under the name CON-CRĒT and brought it to market through Promera in 2007. CON-CRĒT’s performance quickly made believers out of both athletes and bodybuilders. CON-CRĒT’s advantages over traditional creatines, according to the company, include significantly increased solubility, stability, bioavailability and plasma uptake, which all lead to strength, endurance, and recovery from intense workouts, without side effects like cramping, bloating or water retention.
The company claimed CON-CRĒT has been a part of a new generation of supplements and industry initiatives that emphasize ethical standards and provide higher quality to the fitness, athletic, and bodybuilding industries. Customers have become more educated about safety and effectiveness, and thus are attracted to companies that authentically honor quality and are committed to safe, healthy, effective, and legal products. Vireo holds five patents totaling 70 patent claims on its C-HCl compound.